ASCO 2018 | Trial updates in breast cancer from ASCO: TAILORx, PAKT, MONARCH 2 & MONALEESA-3

Each year the American Society of Oncology (ASCO) Annual Meeting presents cutting-edge updates in oncology. Here, Robert Coleman, MBBS, MD, FRCP, FRCPE, of the University of Sheffield, Sheffield, UK, discusses the breast cancer highlights from the 2018 meeting. Dr Colemans picks out the interesting results of the Phase III TAILORx trial (NCT00310180) of chemoendocrine vs. endocrine therapy in hormone receptor-positive, HER2-negative, node-negative breast cancer. In additon, he higlights novel AKT-PI3K pathway-targeting agents for triple negative breast cancer (PAKT; NCT02423603), as well as the use of abemaciclib in pre-menopausal women (MONARCH 2; NCT02107703). Lastly, he discusses a trial of ribociclib plus fulvestrant in the upfront setting (MONALEESA-3; NCT02422615).